An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
University of Pennsylvania
20 participants
Aug 1, 2025
INTERVENTIONAL
Conditions
Summary
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Weekly methotrexate dose of 20 mg (oral or subcutaneous).
Azathioprine dose will be 2-3 mg/kg body weight per day.
Adalimumab dose will be 40 mg subcutaneously every 1-2 weeks
Infliximab dose will be 5mg/kg at week 0 and week 2, and then every 4-8 weeks.
Tocilizumab dose will be 162 mg subcutaneous injection every week or 4-8 mg/kg every 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06941376